TE
ALNY icon

Tema ETFs’s Alnylam Pharmaceuticals ALNY Stock Holding History

Tema ETFs’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$581K Sell
1,930
-42
-2% -$12.7K 0.02% 387
2026
Q1 		$652K Sell
1,972
-24
-1% -$8.17K 0.04% 313
2025
Q4 		$794K Sell
1,996
-567
-22% -$251K 0.06% 276
2025
Q3 		$1.17M Sell
2,563
-2,738
-52% -$1.11M 0.1% 231
2025
Q2 		$1.73M Sell
5,301
-1,174
-18% -$325K 0.46% 78
2025
Q1 		$1.75M Sell
6,475
-9,848
-60% -$2.53M 0.52% 68
2024
Q4 		$3.84M Buy
+16,323
New +$4.29M 1.59% 24

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
PSC
Portman Square Capital London, United Kingdom $2.11B AUM 19.71% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

Tema ETFs's ALNY Position: Q2 2026 in Review

Tema ETFs reduced its Alnylam Pharmaceuticals (ALNY) stake by 2.1% in Q2 2026, selling an estimated $12.7K and leaving 1,930 shares worth $581K. The position accounts for 0.02% of the portfolio, ranked #387.

Tema ETFs first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.84M in Q4 2024. 78 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Tema ETFs held 1,930 shares of Alnylam Pharmaceuticals worth $581K as of Q2 2026.
  • Tema ETFs sold 42 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $12.7K.
  • Alnylam Pharmaceuticals made up 0.02% of Tema ETFs's portfolio in Q2 2026, its #387 holding.
  • Tema ETFs first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Tema ETFs's Alnylam Pharmaceuticals position peaked at $3.84M in Q4 2024.
  • 78 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Tema ETFs's 13F filing for Q2 2026, filed 10 Jul 2026.